(NASDAQ:VTRS), though he revised his price target downward from $15 to $13 ... stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking ...

With a market cap of $14.8 billion, Viatris Inc. (VTRS) is a global pharmaceutical company formed in 2020 through the merger ...

NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc.

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...

Viatris Inc. closed 33.95% short of its 52-week high of $13.55, which the company achieved on November 25th.

(NASDAQ:VTRS) stands against other best Nasdaq stocks ... Reuters cited a Goldman Sachs report highlighting that hedge funds specializing in stock picking and multi-strategy investing saw nearly ...

(NASDAQ:VTRS), though he revised his price target downward from $15 to $ ... If you are looking for an AI stock that is more promising than VTRS but that trades at less than 5 times its earnings ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Viatris Inc. closed 31.37% below its 52-week high of $13.55, which the company reached on November 25th.

Pomerantz LLP is investigating claims on behalf of investors of Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS). Such investors are advised ...